Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT03085914
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
- Conditions
- Locally Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 325
- Registration Number
- NCT03059823
- Locations
- 🇵🇱
Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland
🇵🇱Medical University of Warsaw - 2Nd Department Obstetric and Gynecology, Warsaw, Poland
🇵🇱Centrum Onkologii - Instytut Im. Marii Sklodowskiej - Curie, Warsaw, Poland
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT03039114
- Locations
- 🇮🇹
UO Ematologia ASST Spedali Civili, Brescia, Italy
🇺🇸Clinical Research Alliance, Lake Success, New York, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 47
- Registration Number
- NCT03011372
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇫🇷Chu de Nice - Hospital L Archet, Nice Cedex 3, France
🇩🇪Universitatsklinikum Jena, Jena, Germany
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 307
- Registration Number
- NCT03011892
- Locations
- 🇺🇸
HASSMAN RESEARCH INSTITUTE, LLC, 175 Cross Keys Road, Berlin, New Jersey, United States
🇺🇸ACTIVMED PRACTICES & RESEARCH, INC, 138 Conant Street, Beverly, Massachusetts, United States
🇺🇸CENTER FOR CLINICAL STUDIES (CCS), 1401 Binz, Houston, Texas, United States
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02998476
- Locations
- 🇺🇸
Asclepes Research Centers, Weeki Wachee, Florida, United States
🇺🇸Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
- Conditions
- Advanced MalignanciesSolid TumorsMetastatic Cancer
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT02959437
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
- Conditions
- Pancreatic CancerBreast CancerColorectal Cancer (CRC)Lung Cancer
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT02955940
- Locations
- 🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸New York Oncology Hematology Pc., Clifton Park, New York, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
- Conditions
- MPN (Myeloproliferative Neoplasms)
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 1469
- Registration Number
- NCT02953704
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT02953678